FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
Medical Devices

Unibody Endografts Dont Beat Older Ones: Study

FDA-funded research finds that unibody endografts are not non-inferior to non-unibody devices, leading to updated FDA labeling.

latest-news-card-1
Medical Devices

FDA Reminds on Recalled Exactech Joint Devices

FDA reminds patients and healthcare providers about risks associated with recalled Exactech replacement joint devices that were packaged in defective ...

latest-news-card-1
Human Drugs

Dupixent Meets Key Phase 3 Endpoints: Regeneron

Regeneron and Sanofi say an investigational Phase 3 trial of Dupixent in some COPD patients met all key primary and secondary endpoints.

latest-news-card-1
Biologics

Workforce, Education for Regenerative Medicine

The Government Accountability Office reports on regenerative medicine and advanced therapies workforce and education/training needs.

latest-news-card-1
FDA General

OSTP Goals for Biotechnology and Biomanufacturing

A new White House Office of Science and Technology Policy (OSTP) report lists 10 bold goals for the U.S. biotechnology and biomanufacturing.

latest-news-card-1
Medical Devices

Device Cybersecurity is Top Concern for Shuren

CDRH director Jeff Shuren tells an Alliance for Stronger FDA Webinar that cybersecurity is one of the biggest concerns that keeps him up at night.

latest-news-card-1
Human Drugs

Cidar/Melintas Rezzayo Wins FDA Approval

FDA approves a Cidara Therapeutics and Melinta Therapeutics NDA for Rezzayo (rezafungin for injection) for treating candidemia and invasive candidiasi...

latest-news-card-1
Human Drugs

Complete Response for AbbVie Parkinsons NDA

FDA issues AbbVie a complete response letter for ABBV-951 (foscarbidopa/foslevodopa) for treating motor fluctuations in adults with advanced Parkinson...

latest-news-card-1
Medical Devices

Registry Set Up for Breast Implant Carcinoma Reports

FDA says events involving squamous cell carcinoma in the scar tissue (capsule) that forms around breast implants should be reported to a registry deve...

latest-news-card-1
Federal Register

Shionogis Mulpleta Regulatory Review Period

Federal Register notice: FDA determines for patent extension purposes the regulatory review period for Shionogi & Co.s Mulpleta (lusutrombopag).